Alendronate Tablet
Product Images NDC 60723-205

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 60723-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alendronate 01)

Chemical structure of alendronate sodium, showing its molecular arrangement including amino and phosphate groups with sodium and hydration.*

FDA Label Image

Figure 1 (Alendronate 02)

A line graph depicting cumulative incidence percentage over 36 months comparing Alendronate Sodium and placebo groups. The graph shows lower cumulative incidence for Alendronate Sodium (solid line) compared to placebo (dashed line) throughout the study period.*

FDA Label Image

Figure 2 (Alendronate 03)

A bar chart comparing mean percent increase in Bone Mineral Density (BMD) relative to placebo at three anatomical sites (Lumbar Spine, Femoral Neck, Trochanter) between USA and Multinational groups. The vertical axis shows BMD increase percentages with error bars indicating standard error.*

FDA Label Image

Figure 3 (Alendronate 04)

Two line graphs comparing bone mineral density (BMD) percentage change from baseline over 36 months between Alendronate Sodium 10 mg and placebo groups in a US study and a multinational study. The graphs display BMD change on the y-axis and time in months on the x-axis, showing increases for Alendronate Sodium and flat or decreasing values for placebo.*

FDA Label Image

Figure 4 (Alendronate 05)

Two bar charts depict the mean percentage change in bone mineral density (BMD) from baseline in a 2-year study and a 3-year study. The charts compare Alendronate Sodium 5 mg/day and placebo across lumbar spine, femoral neck, trochanter, and total body sites, showing differences in BMD change with standard error bars.*

FDA Label Image

Figure 5 (Alendronate 06)

A bar chart showing the mean percentage increase in Bone Mineral Density (BMD) relative to placebo with standard error (SE) at three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter. Data are compared between two groups labeled USA and Multinational.*

FDA Label Image

Figure 6 (Alendronate 07)

A line chart showing the mean percentage change from baseline in serum alkaline phosphatase levels over 6 months. The chart compares placebo, Etidronate 400 mg/day, Alendronate Sodium 40 mg/day (multinational study), and Alendronate Sodium 40 mg/day (U.S. study), with sample sizes indicated for each group.*

FDA Label Image

Principal Display Panel (35 mg Tablet Blister Pack Carton)

Packaging label for Alendronate Sodium Tablets, USP 35 mg, showing a 4-tablet carton. Label includes dosage form as tablets, manufacturer Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd, and instructions to dispense medication guide. The label specifies once weekly dosing and includes a barcode and NDC 60723-207-31.*

FDA Label Image

Undefined (Alendronate 09)

Packaging label for Alendronate Sodium Tablets USP 35 mg by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. It includes information on the dosage as once weekly, the package contains 12 tablets (3x4 unit-of-use), a barcode, and instructions for use. The label states prescription only and provides manufacturer details from Hangzhou, China.*

FDA Label Image

Principal Display Panel (35 mg Tablet Blister Pack Carton)

Packaging label for Once Weekly Alendronate Sodium Tablets, USP 35 mg from Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. The label shows a package containing 20 unit-dose tablets (2x10), with instructions indicating Rx only. Storage instructions and manufacturer details are also included on the label.*

FDA Label Image

Principal Display Panel (70 mg Tablet Blister Pack Carton)

Packaging label for Alendronate Sodium Tablets USP, 70 mg, once weekly dosage form. The label includes directions for use, manufacturer information (Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd, Hangzhou, China), and a space to apply a prescription label. The package contains 4 tablets and displays the NDC 60723-205-31. The label is primarily white with blue and black text.*

FDA Label Image

Principal Display Panel (70 mg Tablet Blister Pack Carton)

Alendronate Sodium Tablets, USP 70 mg once weekly, packaging label from Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. The carton is designed for 12 tablets (3x4 unit-of-use) with instructions for prescription use, dosage, and medication guide details. The label includes barcode and manufacturing information.*

FDA Label Image

Principal Display Panel (70 mg Tablet Blister Pack Carton)

Packaging label for Alendronate Sodium Tablets, USP 70 mg, once weekly, produced by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. The label shows a carton designed to hold 20 unit-dose tablets (2x10). It includes usage instructions, storage conditions, and manufacturer details in English.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.